FDA Approves Self-Administered Saphnelo

What Is Saphnelo and How Does It Treat Lupus?

Anifrolumab, marketed as Saphnelo by AstraZeneca, is a fully human IgG1 kappa monoclonal antibody that binds to subunit 1 of the type I interferon receptor (IFNAR1). By blocking signaling from interferon-alpha, interferon-beta, and interferon-omega, the drug interrupts a cytokine cascade that is overactive in the majority of patients with systemic lupus erythematosus (SLE). Genetic and transcriptomic studies have shown that an elevated type I interferon gene signature is present in roughly 60 to 80 percent of adults with SLE and correlates with disease severity.

The drug received its initial FDA approval in August 2021 for adults with moderate to severe SLE who are receiving standard therapy, based on data from the TULIP-1 and TULIP-2 phase 3 trials. In those studies, anifrolumab reduced overall disease activity as measured by the BICLA (BILAG-Based Composite Lupus Assessment) response, and allowed many patients to taper oral corticosteroids — a long-standing goal in lupus care given the cumulative toxicity of long-term steroid use.

Why Does Self-Administration Matter for Lupus Patients?

Until this expanded approval, Saphnelo was delivered as a 300 mg intravenous infusion every four weeks, requiring patients to travel to an infusion center and spend roughly an hour receiving each dose. For a chronic, lifelong condition that disproportionately affects women of reproductive age — many of whom juggle careers, caregiving, and unpredictable disease flares — that logistical load is substantial. A subcutaneous formulation that patients can inject at home using a prefilled syringe or autoinjector pen brings anifrolumab in line with how other biologics for autoimmune disease, such as TNF inhibitors and interleukin blockers, are now routinely delivered.

Beyond convenience, at-home administration may help address well-documented disparities in lupus care. SLE has a higher prevalence and more severe course in Black, Hispanic, and Asian populations, and access to specialty infusion centers is uneven across rural and underserved areas. Removing the infusion-chair bottleneck could expand the pool of patients who can realistically stay on a biologic long term, and rheumatology societies have repeatedly called for treatment options that reduce barriers to consistent immunomodulatory therapy.

What Are the Safety Considerations With Anifrolumab?

The TULIP trial program identified a higher incidence of herpes zoster reactivation and respiratory tract infections in patients receiving anifrolumab compared with placebo. Because type I interferons play a central role in antiviral defense, blocking their signaling carries an inherent infection risk. Prescribing information accordingly recommends updating routine vaccinations — including the recombinant zoster vaccine where appropriate — before initiating therapy, and avoiding live vaccines during treatment.

For self-administration specifically, the FDA typically requires that manufacturers demonstrate patients can correctly use the delivery device through human factors studies, and that clear instructions for storage, handling, and recognizing injection-site reactions or hypersensitivity are provided. Rheumatologists are expected to continue monitoring disease activity, complete blood counts, and infection signs during follow-up, even when the injection itself happens at home.